Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 3/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262742 | 1.00 | ROCK1 (0.40) | ROCK1DYRK2GLSDEGS1ADORA2A | |
| SCHEMBL5261479 | 0.93 | ROCK1 (0.41) | ROCK1DYRK2GLSDEGS1ADORA2A | |
| SCHEMBL5261476 | 0.93 | ROCK1 (0.41) | ROCK1DYRK2GLSDEGS1ADORA2A | |
| SCHEMBL5259908 | 0.92 | ADORA2A (0.40) | ROCK1GLSDEGS1ADORA2ACCKBR | |
| SCHEMBL5259914 | 0.92 | ADORA2A (0.40) | ROCK1GLSDEGS1ADORA2ACCKBR | |
| SCHEMBL5315071 | 0.92 | ADORA2A (0.40) | ROCK1GLSDEGS1ADORA2ACCKBR | |
| SCHEMBL5259144 | 0.91 | GLS (0.39) | ROCK1GLSDEGS1ADORA2ACCKBR | |
| SCHEMBL5259151 | 0.91 | GLS (0.39) | ROCK1GLSDEGS1ADORA2ACCKBR | |
| SCHEMBL5262545 | 0.90 | CACNA1G (0.44) | GLSROCK2NPY5R | |
| SCHEMBL5262654 | 0.90 | CACNA1G (0.44) | GLSROCK2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | claimed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | claimed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | claimed |
| EP-1309590-B1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN (IT) | 2003-01-02 | — | — | US | disclosed |
| US-6486322-B1 | Azaindole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2002-11-26 | — | — | US | disclosed |
| US-6335342-B1 | 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004350-A1 | AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | FFAR4, AZI2, CNKSR1 | ROCK1 2305/4885DYRK2 2150/4885GLS 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.